The biotech firm reported a deeper net loss year-over-year despite higher quarterly revenue of $9 million.
Monte Rosa Therapeutics announced second-quarter revenue of $9 million, up from the prior year. However, its net loss expanded to $43.4 million, compared with $12.3 million in the same period of 2025.
The company’s cash position and financial guidance for the remainder of the year were also highlighted in the release. Last year’s Q2 results had shown a narrower loss, indicating increased spending or investment in the current period.
No immediate market reaction was detailed in the release.